I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therapy ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis Trading Up 1.0 % Shares of Novartis stock opened at $110.69 on Friday. Novartis has a fifty-two week low of $94.72 and a fifty-two week high of $120.92. The company has a debt-to-equity ...

Amid renewed threats of import tariffs on pharmaceuticals from the Trump administration, Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and ...

Novartis plans to build and expand 10 U.S. facilities New facilities include six manufacturing plants and a research and development site The construction will take place over five years, create ...

SAN DIEGO — Novartis, a Swiss pharmaceutical company, announced a planned $23 billion investment over the next five years aimed at expanding its U.S.-based infrastructure. The move ensures that ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...